Pilatus Biosciences Earns FDA Orphan Drug Designation for PLT012
Wednesday, December 11, 2024
Pilatus Biosciences has announced the approval of its leading molecule, PLT012, for the treatment of liver and intrahepatic bile duct cancer (HCC/ICCA).
PLT012 is a humanised anti-CD36 antibody with a distinctive dual mechanism of action (MOA). It simultaneously neutralises immunosuppressive cell populations and enhances the functionality of effector T cells. This molecule has demonstrated potential in addressing various tumors with significant unmet medical needs.
As a monotherapy, PLT012 exhibits remarkable anti-tumour efficacy across both immune "hot" and "cold" tumour models. It significantly increases GzmB-expressing CD8+ T cells while reducing intratumoral Tregs and pro-tumorigenic macrophages.
Moreover, PLT012 modifies the exhaustion characteristics of cytotoxic CD8+ T cells by increasing the populations of progenitor (Texprog) and terminally exhausted (Texterm) T cells, enhancing their tumoricidal activity. When combined with immune checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors, PLT012 showcases improved anti-tumour immune responses.
This approval underscores the groundbreaking scientific advancements achieved by Pilatus Biosciences in addressing critical unmet needs. It further drives the commitment to accelerating PLT012’s development and fostering global collaborations to deliver this transformative treatment to patients with limited therapeutic options.
Source: prnasia.com
